Maligne bolesti kao uzrok smrti kod 92 skladatelja/glazbenika (uključujući ovisnosti)

This study shows malignant diseases as the main cause of death in composers. Pathographies are listed according to the chronological order of their occurrence. Composers in this study died of malignant diseases in the average age of 66.3 years, (median age 67, range 33-91 years). Unfortunately, one part of this heterogeneous group of composers lived too short, while most of them could realize their creative work. Nowadays many of these composers could be cured thanks to the development of medicine, better diagnostic procedures and treatment options, including more selective radiotherapy, chemotherapy, immunotherapy (monoclonal antibodies, specific target receptor or intracellular signal inhibitors).U ovom radu su prikazane maligne bolesti kao glavni uzrok smrti kod 92 skladatelja. Patografije su navedene kronološki. Prosječna dob smrti skladatelja u ovoj studiji je 66,3 godine (medijan dobi 67 godina, raspon 33-91 godine). Nažalost, značajan dio skladatelja nije mogao zbog malignih oboljenja dostići svoj stvaralački opus, dok je ipak većina dostigla stariju dob i stvaralački maksimum. U današnjici bi mnogi od ovih skladatelja mogli biti izliječeni zahvaljujući napretku suvremene medicine, boljim dijagnostičkim postupcima i terapijskim opcijama liječenja. To ponajprije podrazumijeva ciljanu terapiju poput selektivne kemoterapije, imunoterapije (monoklonska protutijela, specifično ciljani inhibitori staničnih receptora ili unutarstaničnih signalnih puteva)

Challenges in anesthesia personalization: resolving the pharmacogenomic puzzle

Clinicians are witnessing differences in the doses required for induction and maintenance of anesthesia, as well as prolonged recovery in some patients. Predictable factors like patient characteristics, factors related to the procedure, pharmacological characteristics of anesthetics and adjunctive drugs, might explain some of the observed differences. However, the role of various polymorphisms of genes encoding for drugs' molecular targets, transporters and metabolic enzymes can have a significant impact on anesthesia outcome, too. In the present paper, we critically discuss pharmacological characteristics of the most common drugs used in anesthesia, with a focus on the possible genetic background of unpredictable diversities in anesthesia outcomes